Scientific article
OA Policy
English

Efficacy and Safety of Dolutegravir Plus Emtricitabine vs Combined Antiretroviral Therapy for the Maintenance of HIV Suppression : Results Through Week 144 of the SIMPL'HIV Trial

Published in

Open forum infectious diseases, vol. 11, no. 11, ofae618

Publication date

2024-11

First online date

2024-10-16

Abstract

The SIMPL'HIV study investigated whether switching to dolutegravir (DTG) + emtricitabine (FTC) was noninferior to continuing combined antiretroviral therapy for maintaining HIV-1 suppression at 144 weeks. The study demonstrated that viral suppression, CD4 gains, adverse events, quality of life, and patient satisfaction were comparable between groups, confirming DTG + FTC's safety and efficacy for long-term management of HIV-1 infection.

Keywords

  • HIV-1 dual therapy
  • Dolutegravir + emtricitabine
  • Maintenance treatment
  • Patient satisfaction
  • Quality of life

UNIGE research groups

Citation (ISO format)

MARINOSCI, Annalisa et al. Efficacy and Safety of Dolutegravir Plus Emtricitabine vs Combined Antiretroviral Therapy for the Maintenance of HIV Suppression : Results Through Week 144 of the SIMPL’HIV Trial. In: Open forum infectious diseases, 2024, vol. 11, n° 11, p. ofae618. doi: 10.1093/ofid/ofae618

Main files (1)

Article (Published version)

Identifiers

Journal ISSN

2328-8957
18views
132downloads

Technical informations

Creation

22/10/2025 09:30:17

First validation

03/12/2025 09:44:30

Update

03/12/2025 09:44:30

Status update

03/12/2025 09:44:30

Last indexation

10/11/2026 18:15:11
All rights reserved by Archive ouverte UNIGE and the University of Geneva
OpenAIRE Indexed & Validated